| Source: Reuters
A Texas court has dismissed a lawsuit brought by the state against drugmaker Merck & Co that sought a refund for money spent on the withdrawn Vioxx pain treatment, the company said on Monday.
Studies showed the painkiller Vioxx had heart side effects years before drugmaker Merck pulled the pill off the market.
| Source: The Associated Press
British drugmaker GlaxoSmithKline PLC said Monday it is temporarily withdrawing its application for U.S. approval of a drug to prevent prostate cancer.
| Source: The Associated Press
Merck & Co. said Monday a district court judge in Texas dismissed all claims in a state Medicaid lawsuit over the painkiller Vioxx.
| Source: The Associated Press
German drugmaker Merck KGaA said Monday the company plans to invest euro150 million ($225 million) in a global research and development center in Beijing for its Serono drugs division.
Friday, 20 Nov 2009 | Source: Reuters
It's not just spending on U.S. healthcare that is breaking records. Drugmakers, insurers and industry groups are on track to spend an all-time high of more than $500 million this year to influence Congress' revamp of the healthcare system.
Friday, 20 Nov 2009 | Source: The Associated Press
Drug developer Merck & Co. said Friday a European advisory committee recommended approval for the company's fertility drug Elonva.
Thursday, 19 Nov 2009 | Source: The Associated Press
Moody's Investors Service issued a negative opinion on the pharmaceutical industry Thursday, saying drugmaker credit ratings will be under pressure until early 2012 because they won't be able to fully replace revenue from best-sellers that go off-patent.
Thursday, 19 Nov 2009 | Source: The Associated Press
Ligand Pharmaceuticals Inc. said Thursday it received a $2 million milestone payment from Merck & Co. as part of a research collaboration.
Wednesday, 18 Nov 2009 | Source: Reuters
Congressional Democrats are seeking government investigations into recent price increases of brand-name prescription drugs, as Congress finalizes an overhaul of the healthcare system.
Tuesday, 17 Nov 2009 | Source: Reuters
High doses of an experimental heart medicine being developed by Merck & Co MRK.N continued to show beneficial effects on both good HDL and bad LDL cholesterol levels eight weeks after patients stopped taking the drug, in a mid-stage study.
Tuesday, 17 Nov 2009 | Source: The Associated Press
Immigrant girls and women will no longer have to be vaccinated against a sexually transmitted virus to get their green cards.
The Dow pared its gains in the final hour of trading after banking analyst Meredith Whitney said the recent market rally is not rooted in fundamentals and the U.S. economy is likely to fall back into a recession next year.
Wednesday, 18 Nov 2009 | Source: The Associated Press
Federal health experts said Wednesday an updated version of Pfizer's best-selling anti-infection vaccine is safe and effective for infants and toddlers, despite company studies that failed to meet certain goals.
Monday, 16 Nov 2009 | Source: The Associated Press
Shares of Merck & Co. rose Monday as Wall Street brushed off the potential for a severe impact from a rival company's sponsored study that showed the cholesterol drug Niaspin is potentially more effective than Merck's Zetia.
Posts |
COMPANY : Merck & Co Inc
With the health care debate continuing, how can investors make money in the sector? Barbara Ryan, managing director and senior pharmaceuticals analyst at Deutsche Bank Securities, and Charles Boorady, health care providers analyst at Citigroup, shared their insights.... Read More
In today's trading session, a total of 50 stocks in the S&P 500 reached new 52-week highs... Read More
20 Nov 2009
Unease about the economy drove many investors to snap up defensive stocks... Read More
20 Nov 2009
Following are the week’s biggest winners and losers... Read More
20 Nov 2009
U.S... Read More
VIDEO | COMPANIES : Merck & Co Inc
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiov...
A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Me...
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Barbara Ryan, pharma analyst at Deutsche Bank Securities...
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.
More Videos
About CNBC | Site Map | Privacy Policy | Terms of Service | Video Reprints | Advertise | Help | Contact
Partners: AOL Money | BloggingStocks.com
Partners: AOL Money | BloggingStocks.com
Data is a real-time snapshot *Data is delayed at least 15 minutesGlobal Business and Financial News, Stock Quotes, and Market Data and Analysis
© 2009 CNBC, Inc. All Rights Reserved.
A Division of NBC Universal
